BD-1047 (dihydrobromide)
CAS No. : 138356-21-5
| Size | Price | Stock |
|---|---|---|
| 5mg | $84 | In-stock |
| 10mg | $108 | In-stock |
| 50mg | $420 | In-stock |
| 100 mg | Get quote | |
| 200 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-16996A |
| M.Wt: | 437.04 |
| Formula: | C13H22Br2Cl2N2 |
| Purity: | >98 % |
| Solubility: | H2O : 25 mg/mL (ultrasonic);DMSO : 25 mg/mL (ultrasonic) |
BD-1047 dihydrobromide is a selective functional antagonist of sigma receptors. BD-1047 dihydrobromide attenuates Apomorphine (HY-12723)-induced climbing and Phencyclidine-induced head twitches[1].
IC50 & Target:sigma-1 receptor[1]
In Vitro: BD-1047 (dihydrobromide) prevents that Cutamesine reduces the cell death rate induced by light exposure in murine photoreceptor-derived 661w cells[2].
BD-1047 (dihydrobromide) attenuates that Cutamesine reduces the mitochondrial damage and the elevated level of caspase 3/7 activity[2].
In Vivo: BD-1047 (dihydrobromide) (1-10 mg/kg; i.p.) decreases the Apomorphine (APO)-induced climbing behavior at the dose of 10 mg/kg in mice[1].
BD-1047 (dihydrobromide) counteracts the antidepressant-like effect induced by co-administration of pramipexole and sertraline (but not pramipexole and fluoxetine)[3].
BD-1047 (dihydrobromide) reduces the increasing expression of pNR1, and reverses the Sig-1 R agonists potentiated NMDA-induced pain behaviour and pNR1 immunoreactivity[4].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- BD-1047 (dihydrobromide)
- Cat. No.:
- HY-16996A
- Quantity:
Your information is safe with us.